Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to Buy at StockNews.com

StockNews.com downgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a strong-buy rating to a buy rating in a report issued on Wednesday morning.

A number of other research analysts also recently issued reports on JAZZ. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Barclays restated an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Morgan Stanley dropped their price objective on Jazz Pharmaceuticals from $183.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $182.79.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $97.81 on Wednesday. The stock has a market cap of $6.03 billion, a price-to-earnings ratio of 13.78, a P/E/G ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals has a twelve month low of $95.49 and a twelve month high of $148.06. The company’s fifty day moving average is $118.96 and its 200 day moving average is $122.11. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. During the same quarter last year, the firm posted $2.68 EPS. The company’s quarterly revenue was down .5% on a year-over-year basis. Sell-side analysts forecast that Jazz Pharmaceuticals will post 16.96 EPS for the current year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total transaction of $116,350.00. Following the transaction, the chief executive officer now owns 439,307 shares in the company, valued at approximately $51,113,369.45. This represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,236 shares of company stock worth $3,956,190 in the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $25,000. Quadrant Capital Group LLC grew its stake in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 101 shares in the last quarter. Hurley Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at about $25,000. Elequin Capital LP lifted its position in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares in the last quarter. Finally, CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth about $28,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.